Loomis Sayles & CO L P Y M Abs Therapeutics, Inc. Transaction History

Loomis Sayles & CO L P

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$25.45 - $37.64 $19.9 Million - $29.4 Million	-782,084 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$29.16 - $51.96 $64,093 - $114,208	-2,198 Reduced 0.28%	782,084 $23.7 Million
Q4 2020 Feb 12, 2021	SELL	$37.86 - $54.26 $176,200 - $252,526	-4,654 Reduced 0.59%	784,282 $38.8 Million
Q3 2020 Nov 12, 2020	BUY	$35.13 - $43.62 $525,158 - $652,075	14,949 Added 1.93%	788,936 $30.3 Million
Q2 2020 Aug 14, 2020	BUY	$23.66 - $49.53 $1.59 Million - $3.32 Million	67,072 Added 9.49%	773,987 $33.4 Million

Q1 2020 May 15, 2020	BUY	$14.39 - $35.8 $2.33 Million - $5.79 Million	161,859 Added 29.7%	706,915 $18.5 Million
Q4 2019 Feb 14, 2020	BUY	$23.81 - $33.78 $13 Million - $18.4 Million	545,056 New	545,056 $17 Million

22.4M

37.4K

48.2K

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $528M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

Stay updated on Loomis Sayles & CO L P with notifications on news.